Experience of the use of silodosin in acute urinary retention caused by benign prostatic hyperplasia
- Autores: Neymark A.I1, Nozdrachyov N.A1
-
Afiliações:
- Edição: Nº 4 (2013)
- Páginas: 47-51
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279911
- ID: 279911
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
For the treatment of acute urinary retention (AUR) as one of the most serious complications of adenoma of the prostate (BPH), α-adrenoblockers are widely used. The article presents an experience of the use of the new uroselective α-adrenoblocker silodosin approved for the treatment of patients with urination disorders caused by BPH. Its pharmacological profile has a number of advantages, including the highest uroselectiveness at the present day, immediate action, the potential for the use of standard dose of 8 mg 1 time a day, which does not require a correction depending on the age, and the possibility of the simultaneous application with antihypertensive drugs.
Palavras-chave
Texto integral
Bibliografia
- Emberton M., Andriole G.L., de la Rosette J. et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003;61: 267-273.
- Marberger M.J., Andersen J.T., Nickel J.C. et al. Prostate Volume and Serum Prostate-Specific Antigen as Predictors of Acute Urinary Retention. Eur. Urol. 2000;38:563-568.
- Clifford G.M., Farmer R.D.T. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur. Urol. 2000;38:2-19.
- Lukacs B, Grange J.C., McCarthy C. et al. Clinical uroselectivity a 3-year follow-up in general practice. BPH Group in General practice. Eur. Urol. 1998;33(Suppl. 2):28-33.
- Lopatkin N.A. (Eds.). Rational pharmacotherapy in Urology. M., 2006:152.
- Tkachuk V.N., Al-Shukri S.H., Lukyanov A.E. Drug treatment of patients with benign prostatic hyperplasia. SPb., 2000:104 p.
- Tatemichi S. et al. Yakugaku Zasshi. 2006;12:209-216.
- Katzung B.G. Basic and Clinical Pharmacology. 6th ed. Norwalk, CT: Appleton & Lange; 1995.
- Schwinn D.A. et al. Mayo Clin Proc. 2004;79:1423-1434.
- Kenny B.A. et al. Br. J Pharmacol. 1996;118:871-878.
- Akiyama K. et al. J Pharm. Exp. Ther. 1999;291:81-91.
- Montorsi F. Profile of silodosin. Eur. Urol. 2010;9 (Suppl.):491-495.
- Marks L.S., Gittelman M.C., Hill L.A. et al. Rapid efficacy of the highly selective α1A-adrenoceptor antagonist silodosin in men with signs and symptoms of BPH: pooled results of two phase 3 studies. J Urol. 2009;181:2634-2640.
Arquivos suplementares
